Antitumor activity of an epithelial cell adhesion molecule-targeted nanovesicular drug delivery system

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 3019-3027

  Hussain, Sajid ^a,c   Plückthun, Andreas ^a   Allen, Theresa M ^b   Zangemeister Wittke, Uwe ^a,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; IMMUNOLIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR LOCALIZATION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; BIOLOGICAL AVAILABILITY; CELL ADHESION MOLECULES; CELL DEATH; CELL LINE, TUMOR; CHOLESTEROL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; EPITHELIAL CELLS; FEMALE; HUMANS; LIPOSOMES; MICE; NANOTECHNOLOGY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 36749016236     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0615     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-30.
2. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
4. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
6. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36.
7. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004;10:2530-7.
8. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
9. Sugano M, Egilmez NK, Yokota SJ, et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60:6942-9.
10. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92.
11. Zalipsky S. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem 1993;4:296-9.
12. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237:99-108.
13. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001;1513:207-16.
14. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31:196-205.
15. Zangemeister-Wittke U. Antibodies for targeted cancer therapy - technical aspects and clinical perspectives. Pathobiology 2005;72:279-86.
16. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab′ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92.
17. Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin Cancer Res 2004;10:1100-11.
18. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631-8.
19. Nellis DF, Ekstrom DL, Kirpotin DB, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 2005;21:205-20.
20. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
21. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48.
22. Munz M, Kieu C, Mack B, et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748-58.
23. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-8.
24. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
25. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-13.
26. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63.
27. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003;9:2837-48.
28. Fitsialos D, Quenneville J, Rasamoelisolo M, et al. A phase I study of VB4-845 in patients with advanced, recurrent head and neck cancer on a weekly dosing scheme. Proc Am Soc Clin Oncol 2005;23:5569.
29. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 2006;5:3170-80.
30. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59:5758-67.
31. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320-30.
32. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979;557:9-23.
33. Pool GL, French ME, Edwards RA, Huang L, Lumb RH. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids 1982;17:448-52.
34. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201-15.
35. Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567-73.
36. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75.
37. Maruyama K, Kennel SJ, Huang L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci U S A 1990;87:5744-8.
38. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63:7400-9.
39. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989;81:1484-8.
40. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40.
41. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
42. Muggia F, Hamilton A. Phase III data on Caelyx in ovarian cancer. Eur J Cancer 2001;37 Suppl 9:15-8.
43. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992;52:5135-43.
44. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. EpCAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46.
45. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:1491.
46. Quenneville J, Fitsialos D, Rasamoelisolo M, et al. A phase I open-label study to evaluate safety, tolerability and pharmacokinetic (PK) profile of VB4-845, an anti-EpCAM immunotoxin, in subjects with SCCHN. Proc Am Soc Clin Oncol 2005;23:55539.
47. Park JW, Hong K, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995;92:1327-31.
48. Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997;413:177-80.
49. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
50. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
51. Goren D, Horowitz AT, Zalipsky S, et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996;74:1749-56.
52. Allen TM, Ahmad I, Lopes de Menezes DE, Moase EH. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem Soc Trans 1995;23:1073-9.